Navigation Links
Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009
Date:9/17/2009

e suppliers, potential competition, the effective management of our growth, our ability to attract and retain key personnel, the potential for products liability claims, government regulation of our business, the challenges associated with developing new products and obtaining and maintaining regulatory approvals if necessary, research and development activities, the lengthy sales cycle for our products, sales employee turnover, changes in our actual or estimated future income, changes in accounting rules, enforceability and the costs of enforcement of our patents, potential infringements of others' patents, the effect of acquisitions and the other factors set forth from time to time in Somanetics' Securities and Exchange Commission filings, including Somanetics' 2008 Annual Report on Form 10-K filed on February 11, 2009 and its 2009 Quarterly Reports on Form 10-Q filed on March 31, 2009 and July 1, 2009.

(Tables to follow)

                                    BALANCE SHEETS

                                                 August 31,  November 30,
                                                    2009         2008
                                                    ----         ----
    ASSETS                                      (Unaudited)   (Audited)
    CURRENT ASSETS:
      Cash and cash equivalents                 $20,724,822  $37,166,141
      Marketable securities                      28,988,437   19,992,545
      Accounts receivable                         7,924,399    7,862,103
      Inventory                                   3,665,636    2,960,422
      Prepaid expenses                              363,007      597,460
      Accrued interest receivable                   184,409       16,667
      Deferred tax asset - current                  164,615      164,615
                                                    -------      -------
        Total current assets                 
'/>"/>
SOURCE Somanetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien
2. Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17, 2009
3. 25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates
4. Somanetics Announces New FDA 510(K) Clearance
5. Somanetics Reports Record Net Revenues and Income Before Income Taxes for Fourth Quarter and Fiscal 2008
6. Somanetics Corporation to Release Fourth Quarter and Fiscal 2008 Financial Results and Host Conference Call January 21, 2009
7. Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
8. Somanetics Announces Share Repurchase Program Increased By $15 Million
9. Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling
10. Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference
11. Somanetics Announces Share Repurchase Program Increased by $15 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NE (PRWEB) March 27, 2015 Ticket Down ... at the CenturyLink Center in Omaha, Nebraska on Friday, ... possibility that more concert dates will be added in Omaha ... of fan demand. , The Garth Brooks World Tour is ... the latest announcement that Garth Brooks and Trisha Yearwood will ...
(Date:3/27/2015)... Endure Yoga is launching WOD (Workout ... This new program matches yoga poses with functional fitness ... down. This program utilizes yoga to improve recovery, prevent ... , Karen Lefurgy, competitive athlete at CrossFit ... I started Crossfit® training, but quickly, due to time ...
(Date:3/27/2015)... 27, 2015 SMI (Silicon Microstructures, Inc.), ... has launched the SM1120 MEMS based ultra-miniature pressure sensor ... microsensor profile at only 220um x 75um provides ample ... challenging locations. With industry leading in vivo drift ... provides a broad operating pressure range from 0 to ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Operatic contenders ... of greatness on April 17th. The universally acclaimed baritone ... the 9th annual Opera Idol at The Merion in ... competition, which has drawn aspiring opera singers from around ... showcases some of the finest young talent in the ...
(Date:3/27/2015)... The 2015 Deep Market Research Report ... in-depth study on the current state of the ... on the Chinese situation. , The report provides ... classifications, applications and industry chain structure. The Glutathione ... and Chinese domestic situations including development trends, competitive ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... in our environment that may cause breast cancer . ... linked to breast cancer has listed 216 compounds, many of ... extensive review of 900 scientific studies concerning humans and rodents ... and water that appear to be a reason behind breast ...
... toll the world over. Almost 100 million girls die every year, ... ,According to a searing report on the prejudices against women, "Because ... developing countries, where a male child remains more valued. ... child development agency - highlights the fact that two million girls ...
... Researchers at University of Southern Maine in Portland have revealed ... far the US government has been denying the possibility. ... Laboratories in New Mexico found that people exposed to DU ... ,DU is a dense, inadequately radioactive metal that is ...
... of North Carolina, Chapel Hill, have found out that middle-aged ... are at a higher risk of retinopathy than others. ... of the eye that can lead to severe vision problems ... the headache history and eye health of 10,902 men and ...
... same level of active therapeutic chemical and produces the ... the harmful toxins, according to UCSF researchers. ... of the active ingredient delta-9-tertrahydrocannibinol, or THC, are reported ... and Therapeutics." ,"We showed in a recent ...
... claimed significant success in the continuing fight to develop ... ,Thomas Pento and Roger HarrisonTwo professors say ... the spread of certain cancerous cells without damaging healthy, ... in fighting lung, prostate and pancreatic cancers without the ...
Cached Medicine News:Health News:List of Compounds That Causes Breast Cancer Identified 2Health News:Female Infanticide and Feticide Continue to Increase 2Health News:History of Migraines Linked to Increased Risk of Retinopathy 2Health News:Smokeless Cannabis Delivery Device Found Efficient and Less Toxic 2Health News:US Professors Develop Fusion Protein to Fight Cancer 2
(Date:3/27/2015)... Wis. , March 27, 2015 ... unit shipments of incontinence devices for women. ... but the most gratifying part is the hundreds ... from women whose lives have been positively impacted ... president of InControl. InControl recently released ...
(Date:3/27/2015)... 27, 2015 RnRMarketResearch.com adds ... market research report of 52 pages with latest ... intelligence library. The report "Visceral Pain - Pipeline ... therapeutic development for Visceral Pain, complete with comparative ... target, mechanism of action (MoA), route of administration ...
(Date:3/26/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... on Omega-3 therapies for cardiovascular disease and overall health, ... common shares of the Corporation (the "Common Shares"). The ... of December 5 th , 2014 to March 4 ... is due on or before April 1, 2015. Interest ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... - Millennium on track to file sNDA in ... 18 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... large, international Phase III VISTA(1) trial in,patients with ... of,VELCADE, melphalan and prednisone (VMP) demonstrated a highly ...
... 10 minutes - - Landmark Study Reported in ... 18 A landmark publication that,appeared in the Journal ... site blinded clinical study. The paper is entitled "The ... Accuracy of,Melanoma and Equivocal Melanocytic Lesions." The study, ...
Cached Medicine Technology:Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 2Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 3Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 4Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 5Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 6Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 2Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 3
... A CMV assay for screening donors on ... CMV-PA System uses CMV antigen attached to ... cytomegalovirus. Relative sensitivity and specificity of the ... 99.8% and 99.3% respectively. The use of ...
... microplate agglutination technology. Its is a fully ... testing. PK7200 also handles weak D as ... The Automated Microplate System delivers the very ... that for the past generation has tested ...
... fully automated blood bank ... American market based on ... The ORTHO ProVue™ eliminates ... increasing productivity via random ...
... are in need of MRI exams, many ... scanners. They have heard of, or experienced ... and noisy tubes of supercon scanners - ... people want is a patient-friendly MRI. Now ...
Medicine Products: